Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors [0.03%]
双特异抗体偶联药物对EGFR和HER2的双重靶向作用在多种实体瘤中显示出广谱抗肿瘤活性
Xiaojuan Chai,Fu Li,Hongmei Xie et al.
Xiaojuan Chai et al.
While HER2-directed antibody-drug conjugates (ADCs), such as ENHERTU® (DS-8201), represent a major therapeutic advance, treatment options for tumors with low HER2 expression remain limited, and acquired resistance continues to pose a signi...
Retraction: Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma [0.03%]
撤稿：SAPK2/p38抑制通过阻断IRES介导的翻译起始增强mTORC1抑制在胶质母细胞瘤中的敏感性
Cheri Cloninger,Andrew Bernath,Tariq Bashir et al.
Cheri Cloninger et al.
Retraction: Mammalian Target of Rapamycin Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Up-regulating the Insulin-like Growth Factor Receptor/Insulin Receptor Substrate-1/Phosphatidylinositol 3-Kinase Cascade [0.03%]
撤稿：哺乳动物雷帕霉素靶蛋白抑制剂通过上调胰岛素样生长因子受体/胰岛素受体底物-1/磷脂酰肌醇3-激酶通路激活多发性骨髓瘤细胞中的丝裂原活化蛋白激酶信号转导路径
Yijiang Shi,Huajun Yan,Patrick Frost et al.
Yijiang Shi et al.
Retraction: A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity [0.03%]
撤稿：一种新型疗法通过降解DEPTOR诱导多发性骨髓瘤细胞毒性
Mario I Vega,Yijiang Shi,Patrick Frost et al.
Mario I Vega et al.
Editor's Note: Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer [0.03%]
编辑部：顺氯氨铂通过产生反应性氧上调血管紧张素Ⅱ受体1并增强膀胱癌细胞VEGF的生成
Nobuyuki Tanaka,Akira Miyajima,Takeo Kosaka et al.
Nobuyuki Tanaka et al.
Published Erratum
Molecular cancer therapeutics. 2026 Aug 4;25(8):1410. DOI:10.1158/1535-7163.MCT-26-0612 2026
Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer [0.03%]
纠正：ONC212是一种新型线粒体抑制剂，可与糖酵解抑制协同作用以治疗胰腺癌
Isacco Ferrarini,Anna Louie,Lanlan Zhou et al.
Isacco Ferrarini et al.
Published Erratum
Molecular cancer therapeutics. 2026 Aug 4;25(8):1408. DOI:10.1158/1535-7163.MCT-26-0613 2026
Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer [0.03%]
关于：热休克蛋白90抑制可改变胰腺星形细胞的激活并增强PD-1阻断在胰腺癌中的疗效的更正通知
Yuchen Zhang,Michael B Ware,Mohammad Y Zaidi et al.
Yuchen Zhang et al.
Published Erratum
Molecular cancer therapeutics. 2026 Aug 4;25(8):1409. DOI:10.1158/1535-7163.MCT-26-0614 2026
Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations [0.03%]
一种口服环状多肽LUNA18通过直接泛RAS抑制作用展示出针对不同RAS基因突变的抗肿瘤活性
Hitoshi Sase,Saki Michisaka,Yukako Tachibana et al.
Hitoshi Sase et al.
Although recent extensive efforts led to the landmark discovery of clinically effective KRASG12C inhibitors (KRASG12C-i), targeting RAS genetic alterations beyond the G12C mutant remains challenging. Here we report on LUNA18 (paluratide), a...
AZ'4331 is a novel pan-TEAD auto-palmitoylation inhibitor for the treatment of Hippo pathway-altered cancers [0.03%]
AZ'4331是一种新型泛TEAD自动棕榈酰化抑制剂，可用于治疗Hippo信号通路改变的癌症
Danielle J Sanchez,Jacob A Gordon,Ryan Richards et al.
Danielle J Sanchez et al.
TEAD proteins are the transcriptional effectors of the Hippo signaling pathway that bind coactivators YAP/TAZ to activate gene expression programs involved in cell survival, proliferation, and drug resistance. TEAD-dependent transcription i...
Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer [0.03%]
凡丁胺治疗导致的激酶可塑性增强雌激素受体阳性乳腺癌对他莫昔芬的敏感性
Austin A Whitman,Rasha T Kakati,Santiago Haase et al.
Austin A Whitman et al.
Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib t...